GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the ticker ONCT.

GTx Inc. (NASDAQ:GTXI) and Oncternal said the merger will combine Oncternal’s clinical stage oncology pipeline with GTx’s preclinical selective androgen receptor degrader (SARD) program for castration-resistant prostate cancer (CRPC)...